FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL				
OMB Number:	3235-0287			
Estimated average bur	den			

	-	-
	OMB Number:	3235-0287
	Estimated average bur	den
	hours per response:	0.5
-		

	tion 1(b).	ue. 3ee		File							urities Exchan Company Act					nours per	response		0.5
1. Name and Address of Reporting Person [*] JOHNSON & JOHNSON				<u>A</u>	2. Issuer Name and Ticker or Trading Symbol <u>AQUINOX PHARMACEUTICALS, INC</u> [AQXP]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title Other (specify							
(Last) ONE JOI	(Fii HNSON & .	rst) (JOHNSON PLA	Middle ZA)		Date of (16/20		st Trar	nsactio	n (Mor	th/Day/Year)			belov	w)		be	elow)	
(Street) NEW NJ 08933 BRUNSWICK				4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year) Form filed by One Reporting Person Amendment, Date of Original Filed (Month/Day/Year) Form filed by One Reporting Person Amendment, Date of Original Filed (Month/Day/Year) Form filed by More than One Reporting Person														
(City)	(St		Zip)																
		Tabl	e I -	Non-Deriv	/ative	e Sec	uritie		-	ed, D	isposed o	of, or E	Benefici	ally Owne	ed				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye			Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Ī	Code	v	Amount	(A) or (D)	Price	Reported Transaction (Instr. 3 and	n(s) d 4)			(Instr.	. 4)
Common	Stock			12/16/20)14				S		6,507	D	\$7.63 ⁽²⁾	1,343,0	687	I		John Deve	ison & ison elopment poration ⁽¹⁾
Common Stock 12/17/201)14				S		1,593	D	\$7.58 ⁽³⁾	1,342,0	094	I		John Deve	ison & ison elopment poration ⁽¹⁾		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	of 2. 3. Transaction 3A. Deemed 4. Ve Conversion Date Execution Date, Transaction or Exercise (Month/Day/Year) if any Code (Instr.		action	5. Nu of Deriv Secu Acqu (A) of Dispo of (D) (Instr and 5	mber ative rities ired osed . 3, 4	6. Da	ate Exe iration I	ercisable and 7. Date Ar y/Year) Se Ur De		e and nt of ities lying itive ty (Instr. 3	8. Price of 9. 1 Derivative de Security Se (Instr. 5) Be Ov 3 Re		ing ed ction(s)	Form: Direct (or Indir	Ownership of				
					Code	v	(A)	(D)	Date	e rcisable	Expiration Date	Title	Amount or Number of Shares						

1. Name and Address of Reporting Person* JOHNSON & JOHNSON

(Last) (First) (Middle) **ONE JOHNSON & JOHNSON PLAZA**

(Street) NEW BRUNSWICK	NJ	08933
(City)	(State)	(Zip)
1. Name and Address JOHNSON & CORP ET AL	JOHNSON I	ion [°] DEVELOPMENT
(Last) ONE JOHNSON	(First) & JOHNSON P	(Middle) PLAZA
(Street)		

BRUNSWICK

(City)	(State)	(Zip)	

Explanation of Responses:

1. The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$7.60 to \$7.70. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$7.52 to \$7.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Remarks:

Douglas Chia, Secretary of 12/17/2014 Johnson & Johnson Steven M. Rosenberg, Secretary of Johnson & 12/17/2014 Johnson Development **Corporation**

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.